Briacell Therapeutics Corp BCTX

$4.05 -0.11 (-2.53%)

Valuation

Market cap
37,540,000
Revenue TTM
$0
Net income TTM
$-26,310,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
80,554
Avg volume
321,314
Day's range
$3.97 – $4.20
Shares out
8,700,000
Stochastic %K
70%
Beta
1.10
Analysts
Strong Buy
Price target
$40.00

Price

Company profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator...

Show more

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 921 1810
Website
https://briacell.com
Address
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Latest news

Stocktwits

FredFlintstock Sep 29, 4:23 PM
$BCTX its a pipe dream
0 replies
SmallCapVoice Sep 29, 1:25 PM
BriaCell Therapeutics $BCTX is featured by Samba Scientific in the latest article, “BriaCell Bets on a More Accessible Cell Therapy,” featuring Dr. William Williams. Read this feature and other recent media coverage here: https://briacell.com/media-coverage/
0 replies
BHWinehouse Sep 29, 12:16 PM
$BCTX https://sambasci.com/blog/briacell-bets-on-a-more-accessible-cell-therapy/?fbclid=IwVERDUAUoizhleHRuA2FlbQIxMABwZG9mBXNydGMGYXBwX2lkDDM1MDY4NTUzMTcyOAABHiB95uJ1ucglyDPv846T6IcsDIR0vcIFCHygCQ8MS1ursCChsLwHZA7pLOeZ_aem_pKa12YhbNu0C3wE04-EaZQ
0 replies
AliceFireSteam Sep 28, 8:33 PM
$BCTX
0 replies
Biotechlineup Sep 28, 11:43 AM
$BCTX Bria Cell is participating in a Renmark Virtual Non-Deal Roadshow Tuesday. Event Details Date, Next Tuesday, September 29, 2026 Time: 2:00 p.m. Eastern Time (11:00 AM PDT) Place, Virtual / Online Webcast Presenters: CEO Dr. William Williams and Jamieson Bondarenko R Renmark Financi... Pre -submit questions for management when signing up. BriaCell's science is highly regarded—their lead asset Bria-IMT received its 7th consecutive positive safety recommendation from the independent Data Safety Monitoring Board (DSMB) for their Phase 3 metastatic breast cancer study. Bctx recently expanded its Phase 3 trial to major institutions like Memorial Sloan Kettering and NYU Langone. We are looking forward to management further confirmation of the trial progress , timeline and cash run . https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-tsx-bct-nasdaq-bctx-3BBWyRF7_t
0 replies
2maligators Sep 25, 6:20 PM
$BCTX
0 replies
letsdodiz Sep 25, 3:41 PM
$BCTX If anyone has questions that you want management to answer in the next Tuesdays presentation ask it in the comments when you register for the event.
4 replies
BHWinehouse Sep 25, 10:11 AM
$BCTX Their thought processes for timing of recent (June) financing, 144 events PR announcement, cash runway and partnerships are all discussed here. Still a very worthy watch if you are new here... https://renmark-drupal.s3.amazonaws.com/vndr/briacell-therapeutics-corp/2026-06-25-11-00-00/index.html
1 replies